Elysium Therapeutics Announces Webcast on SOOPR™ and Fentanyl Rebound Challenge in Opioid Crisis

Elysium Therapeutics to Host Investor Webcast



Elysium Therapeutics, an innovative biopharmaceutical company, has announced it will conduct an investor webcast focusing on its groundbreaking Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) program. This initiative aims to combat a grave issue in today’s opioid crisis: the phenomenon known as fentanyl rebound, or re-narcotization.

The webcast will take place on May 19, 2025 at 2:00 PM ET and will feature insights from Co-Founder and CEO Greg Sturmer along with CSO Tom Jenkins, Ph.D. Their discussion will spotlight the urgent necessity for advanced rescue medications targeting overdose incidents associated with synthetic opioids, particularly fentanyl. The opioid epidemic continues to escalate, and with it, the critical need to address complications such as fentanyl rebound, which poses severe risks including respiratory distress, brain damage, and even fatalities.

"There is a pressing need to raise awareness around fentanyl rebound, which impacts patients who overdose on synthetic opioids, leading to devastating health consequences," Greg Sturmer shared. He noted that existing short-acting opioid antagonists, like Narcan® and Opvee®, are typically designed for overdoses from conventional opioids such as heroin but often fall short in effectively reversing the effects of synthetic opioids like fentanyl. This disconnect highlights the inadequacy of current rescue agents in responding to the opioid crisis's complexities.

Sturmer elaborated on SOOPR as a pioneering solution, stating that it is crafted specifically to target the fentanyl rebound issue, presenting a potential breakthrough in opioid overdose therapy. Unlike current options, SOOPR is developed with a focus on rapid onset and long-duration action, which is vital for effectively managing fentanyl overdoses.

Understanding SOOPR™


The SOOPR program represents a step forward in overdose prevention and reversal. Using a proprietary formulation of long-acting naloxone, SOOPR promises quicker efficacy than Narcan® via an innovative long-acting injection (LAI) technology. The formulation is designed to effectively restore respiration and provide a blocking effect from opioids for 18 to 24 hours, significantly lowering the risk of re-narcotization and safeguarding patients from same-day opioid re-use.

Such advancements in opioid treatment options have garnered support from first responders and professionals in opioid use disorder (OUD) treatment. Their endorsement reinforces the pressing need for this advanced therapy amid the ongoing opioid crisis, which has seen thousands of preventable deaths each year due to inadequate response methods.

During the webcast, audience members will gain valuable insights into the challenges posed by fentanyl and the potential of SOOPR to reshape the landscape of overdose response.

Register for the Webcast


Investors and interested parties are encouraged to register for the webcast through the Zoom platform, using the details below:


In conclusion, Elysium Therapeutics emphasizes its commitment to establishing higher safety standards in the opioid industry through the development of its SMART™ (Safer Medicines Alleviate Risks and Trauma) products. As part of this initiative, SOOPR stands out as a hallmark in the fight against the opioid crisis, aiming not only to reverse overdoses but also to mitigate risks associated with opioid use, thus seeking to alleviate the global suffering caused by opioid-use disorders. For more detailed information about Elysium Therapeutics and their ongoing projects, visit their official website at elysiumrx.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.